Cartesian Therapeutics Stock Analysis
RNAC Stock | 17.12 0.19 1.12% |
Cartesian Therapeutics is overvalued with Real Value of 9.17 and Target Price of 3.5. The main objective of Cartesian Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Cartesian Therapeutics is worth, separate from its market price. There are two main types of Cartesian Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Cartesian Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Cartesian Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Cartesian |
Cartesian Stock Analysis Notes
About 58.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 47.22. Cartesian Therapeutics had not issued any dividends in recent years. The entity had 1:30 split on the 5th of April 2024. To find out more about Cartesian Therapeutics contact Carsten Brunn at 617 923 1400 or learn more at https://www.cartesiantherapeutics.com.Cartesian Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cartesian Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cartesian Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Cartesian Therapeutics had very high historical volatility over the last 90 days | |
Cartesian Therapeutics was previously known as SELB Old and was traded on NASDAQ Exchange under the symbol SELB. | |
The company reported the previous year's revenue of 26 M. Net Loss for the year was (219.71 M) with profit before overhead, payroll, taxes, and interest of 38.4 M. | |
Cartesian Therapeutics currently holds about 106.44 M in cash with (51.16 M) of positive cash flow from operations. | |
Roughly 58.0% of the company outstanding shares are owned by corporate insiders | |
Latest headline from thelincolnianonline.com: Cartesian Therapeutics Buy Rating Reiterated at Needham Company LLC |
Cartesian Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cartesian Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
7th of March 2024 Upcoming Quarterly Report | View | |
2nd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
7th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Cartesian Largest EPS Surprises
Earnings surprises can significantly impact Cartesian Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2023-08-17 | 2023-06-30 | -0.08 | -0.07 | 0.01 | 12 | ||
2021-03-11 | 2020-12-31 | -0.12 | -0.14 | -0.02 | 16 | ||
2024-03-07 | 2023-12-31 | -0.04 | -0.07 | -0.03 | 75 |
Cartesian Stock Institutional Investors
Shares | Nuveen Asset Management, Llc | 2024-06-30 | 34.8 K | Northern Trust Corp | 2024-06-30 | 30.9 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 30 K | Sphera Funds Management Ltd. | 2024-06-30 | 25.1 K | Delphi Financial Group Inc | 2024-06-30 | 22 K | Bank Of New York Mellon Corp | 2024-06-30 | 19.9 K | Charles Schwab Investment Management Inc | 2024-06-30 | 19 K | Renaissance Technologies Corp | 2024-06-30 | 17.1 K | Lake Street Advisors Group, Llc | 2024-09-30 | 15.8 K | Fmr Inc | 2024-06-30 | 510.8 K | Blackrock Inc | 2024-06-30 | 407.6 K |
Cartesian Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 430.27 M.Cartesian Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (2.07) | (1.96) | |
Return On Capital Employed | (0.36) | (0.38) | |
Return On Assets | (0.72) | (0.76) | |
Return On Equity | 0.50 | 0.53 |
Management Efficiency
Cartesian Therapeutics has return on total asset (ROA) of (0.1095) % which means that it has lost $0.1095 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (70.2926) %, meaning that it created substantial loss on money invested by shareholders. Cartesian Therapeutics' management efficiency ratios could be used to measure how well Cartesian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.53, whereas Return On Tangible Assets are projected to grow to (1.96). At present, Cartesian Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 225 M, whereas Non Currrent Assets Other are forecasted to decline to about 1.2 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | (85.14) | (80.88) | |
Tangible Book Value Per Share | (123.58) | (117.40) | |
Enterprise Value Over EBITDA | (0.15) | (0.16) | |
Price Book Value Ratio | (0.23) | (0.22) | |
Enterprise Value Multiple | (0.15) | (0.16) | |
Price Fair Value | (0.23) | (0.22) | |
Enterprise Value | 35.7 M | 33.9 M |
Evaluating the management effectiveness of Cartesian Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Cartesian Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Operating Margin (45.41) | Beta 0.832 | Return On Assets (0.11) | Return On Equity (70.29) |
Technical Drivers
As of the 14th of November 2024, Cartesian Therapeutics shows the Mean Deviation of 4.79, risk adjusted performance of 0.0729, and Downside Deviation of 5.64. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Cartesian Therapeutics, as well as the relationship between them.Cartesian Therapeutics Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cartesian Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cartesian Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Cartesian Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cartesian Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cartesian Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cartesian Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cartesian Therapeutics Outstanding Bonds
Cartesian Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cartesian Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cartesian bonds can be classified according to their maturity, which is the date when Cartesian Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
International Game Technology Corp BondUS460599AD57 | View | |
Valero Energy Partners Corp BondUS91914JAA07 | View |
Cartesian Therapeutics Predictive Daily Indicators
Cartesian Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cartesian Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cartesian Therapeutics Corporate Filings
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 15th of October 2024 An amendment to the original Schedule 13D filing | ViewVerify |
F4 | 4th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
1st of October 2024 Other Reports | ViewVerify | |
F4 | 27th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 26th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 23rd of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
20th of September 2024 Other Reports | ViewVerify |
Cartesian Therapeutics Forecast Models
Cartesian Therapeutics' time-series forecasting models are one of many Cartesian Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cartesian Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Cartesian Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Cartesian Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cartesian shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cartesian Therapeutics. By using and applying Cartesian Stock analysis, traders can create a robust methodology for identifying Cartesian entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (9.18) | (9.64) | |
Operating Profit Margin | (3.32) | (3.49) | |
Net Loss | (8.45) | (8.87) | |
Gross Profit Margin | 0.94 | 1.06 |
Current Cartesian Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cartesian analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cartesian analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
3.5 | Strong Buy | 6 | Odds |
Most Cartesian analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cartesian stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cartesian Therapeutics, talking to its executives and customers, or listening to Cartesian conference calls.
Cartesian Stock Analysis Indicators
Cartesian Therapeutics stock analysis indicators help investors evaluate how Cartesian Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cartesian Therapeutics shares will generate the highest return on investment. By understating and applying Cartesian Therapeutics stock analysis, traders can identify Cartesian Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 108 M | |
Common Stock Shares Outstanding | 5.2 M | |
Total Stockholder Equity | -440.2 M | |
Tax Provision | -19 M | |
Quarterly Earnings Growth Y O Y | 0.537 | |
Property Plant And Equipment Net | 12.2 M | |
Cash And Short Term Investments | 76.9 M | |
Cash | 76.9 M | |
Accounts Payable | 3.1 M | |
Net Debt | -66 M | |
50 Day M A | 18.9618 | |
Total Current Liabilities | 68.2 M | |
Other Operating Expenses | 112.4 M | |
Non Current Assets Total | 214.3 M | |
Forward Price Earnings | 25.4453 | |
Non Currrent Assets Other | 1.4 M | |
Stock Based Compensation | 22.5 M |
Complementary Tools for Cartesian Stock analysis
When running Cartesian Therapeutics' price analysis, check to measure Cartesian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cartesian Therapeutics is operating at the current time. Most of Cartesian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cartesian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cartesian Therapeutics' price. Additionally, you may evaluate how the addition of Cartesian Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |